Dec 18, 2018 - A number of companies suffered setbacks this year.
Dec 17, 2018 - Incyte (INCY) collaborates with Innovent for the development of three clinical-stage product candidates: pemigatinib, itacitinib and parsaclisib.
Dec 12, 2018 - Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
Dec 10, 2018 - Here are five stocks that are attractive and most likely to be takeout targets in 2019.
Dec 04, 2018 - Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
Nov 19, 2018 - AstraZeneca (AZN) announced that Imfinzi as a monotherapy or in combination with tremelimumab failed to improve overall survival in first-line NSCLC. The combination had also failed to improve progression free survival last year.
Nov 12, 2018 - Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
Oct 30, 2018 - INCY earnings call for the period ending September 30, 2018.
Oct 30, 2018 -
Oct 24, 2018 - Earnings releases and key data-read outs were the key developments in the biotech sector last week.